Table 3 Availability of outcome data by trial subgroup
Trial characteristic | Total trials; n | Registry has results within 12 months of trial completion; n (%) | Months elapsed from completion to results in registry; median (IQR) | Publication within 24 months of trial completion; n (%) | Months elapsed from completion to publication; median (IQR) |
|---|---|---|---|---|---|
Total | 333 | 15 (5%) | 42 (16–76) | 129 (39%) | 21 (9–34) |
Infection | |||||
H1N1 | 261 | 11 (4%) | 45 (18–78) | 94 (36%) | 23 (12–34) |
Ebola | 60 | 4 (7%) | 16 (12–43) | 29 (48%) | 11 (-2–34) |
Zika | 12 | 0 (0%) | 6 (50%) | -3 (-11–18) | |
Funding Source | |||||
Industry | 206 | 8 (4%) | 48 (22–80) | 71 (35%) | 24 (10–34) |
Federal Government | 94 | 7 (7%) | 14 (13–24) | 47 (50%) | 17 (6–28) |
University | 89 | 2 (2%) | 51 (18–75) | 49 (55%) | 15 (6–27) |
Other | 35 | 2 (6%) | 16 (6–32) | 16 (46%) | 10 (1–28) |
Trial Phase | |||||
Phase I | 59 | 1 (2%) | 42 (16–49) | 24 (41%) | 17 (-4–40) |
Phase II | 96 | 11 (12%) | 25 (13–73) | 43 (45%) | 19 (5–28) |
Phase III | 79 | 1 (1%) | 43 (21–80) | 23 (29%) | 28 (18–34) |
Phase IV | 54 | 1 (2%) | 65 (24–85) | 21 (39%) | 19 (12–36) |
Other | 45 | 1 (2%) | 21 (14–79) | 18 (40%) | 18 (9–38) |
Intervention Type | |||||
Drug/biologic | 44 | 0 (0%) | 32 (19–59) | 17 (39%) | 19 (9–34) |
Vaccine | 276 | 15 (5%) | 43 (16–78) | 108 (39%) | 22 (9–34) |
Other | 13 | 0 (0%) | 4 (31%) | 22 (13–48) | |
Recruiting Status in Registry | |||||
Enrollment completed | 286 | 15 (5%) | 41 (16–76) | 118 (41%) | 21 (9–34) |
Enrollment not complete | 11 | 0 (0%) | 2 (18%) | 41 (16–73) | |
Stopped early | 16 | 0 (0%) | 49 (21–75) | 2 (13%) | 21 (7–41) |
Suspended/not currently enrolling | 4 | 0 (0%) | 1 (25%) | ||
Unknown status | 16 | 0 (0%) | 6 (38%) | 13 (5–25) | |